Check-Cap (CHEK)

• Market cap: $3.45M
• 1 day: 3.44%
• 5 days: -3.45%
• 1 month: -22.53%
• 3 months: -65.09%
• 6 months: -73.54%
• Year to date: -70.65%
• 1 year: -73.89%
• 5 years: -98.23%
• 10 years: -99.96%

About: Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Employees: 85

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

27% more funds holding

Funds holding: 11 [Q2] → 14 (+3) [Q3]

0.03% more ownership

Funds ownership: 0.14% [Q2] → 0.17% (+0.03%) [Q3]

24% less capital invested

Capital invested by funds: $16.3K [Q2] → $12.5K (-$3.84K) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1